Everyday LipidHealth & Nutrition Review中文
HEALTH & NUTRITION REVIEW · COMPREHENSIVE IMMUNOLOGY

A Comprehensive Review of the Human Immune System

Understanding immune composition, coordinated responses, aging, and the evidence for health interventions

Swipe wide figures and tables sideways to read their full labels on small screens.

Review overview

The immune system is a body-wide network of cells, tissues, organs, and molecules that controls infection, helps monitor abnormal cells, maintains tissue homeostasis, and supports repair. Healthy responses require activation and restraint: stronger activity is not always healthier. Age-related changes can affect infection risk and responses to some vaccines, but cells, tissues, and individuals do not follow one uniform decline curve.

Understanding immune health means asking how the body recognizes threats, organizes defense, stores memory, and brings responses to an end. It also means distinguishing biological mechanisms from evidence of less illness. This review moves from immune composition and function to aging, influences, and research on lifestyle, nutrition, and medical interventions.[1][29][37]

Definition and composition of the immune system

Immunity encompasses defense, tolerance, memory, and repair. Responses must control infection while limiting inappropriate reactions to self tissues and many harmless substances.[1][29]

1. Innate immune cells

2. Adaptive immune cells

3. Immune signaling

Cytokines connect immune and tissue responses. Effects of IL-6, TNF, IL-10, TGF-β, and interferons depend on dose, timing, receptors, and location. Chronic low-grade inflammation relates to some age-associated changes but does not explain every person or process.[4][29][33]

4. Research on interventions for immune health

Calorie restriction, metformin, rapamycin, senolytics, vitamin D, and omega-3 involve different mechanisms and stages of evidence and use. Adequate nutrition is a basic need; calorie restriction requires attention to nutritional and physical status; drug mechanisms, animal results, and early immune measurements do not automatically establish clinical protection in healthy people. These topics are discussed separately below.[5][14][16][17][26][27]

Supplementary Figure S1 · The organ network and coordinated immune defense
A · Where are immune responses organized?
ThymusT-cell maturation and selectionSupports appropriate recognitionSkin and mucosaLimit entry of pathogensAlso host local immune responsesBone marrowProvides immune-cell precursorsSupports ongoing blood-cell productionLymph nodesCollect information from tissuesOrganize communication and responsesSpleenSamples information from bloodResponds to blood-borne threatsBlood and lymph connect the network; positions are schematic, not an anatomical scale drawing.
B · How do the components cooperate?
BarriersSkin and mucosaLimit entryRapid recognitionPhagocytes, NK cellsComplement and signalsTargeting + memoryT cells coordinate and killB/plasma cells: antibodiesResolution + repairClear threat and debrisControl damage, restore balanceProcesses overlap and feed back; arrows show teaching relationships, not measured timing or strength.
Panel A shows organ functions and schematic locations; panel B shows overlapping defense tasks. Both are teaching schematics based on NIAID, not anatomical scale drawings, measured data, or a universal infection time course.[1]
Supplementary Table S1. Roles of immune cells and molecules [1][29]
ComponentRoleInterpretation
NeutrophilsChemotaxis, phagocytosis, granules; extracellular traps in some conditionsCounts, migration, and antimicrobial activity differ
MacrophagesClear microbes/debris; signal, repair, and contribute to fibrosisLocation and activation state shape effects
Dendritic cellsAcquire/present antigen and organize T-cell activationLink innate recognition with adaptive responses
Natural killer (NK) cellsIntegrate activating/inhibitory signals against some abnormal targetsCounts cannot replace functional assays
T cellsCD4 help, CD8 killing, regulatory restraint; some form memorySubsets and antigen-specific responses differ
B / plasma cellsAntigen recognition; plasma-cell antibodies; B-cell memoryAntibodies, protection, and illness duration differ
ComplementLabels targets, amplifies responses, helps clear some pathogensRequires regulation to avoid tissue injury

How the immune system works

Four interacting tasks help explain a response; in practice they overlap:

  1. Innate response: pattern-recognition receptors, including TLRs, detect microbial features or damage signals and initiate phagocytosis, cytokines, and other early activity.
  2. Antigen presentation: dendritic cells display antigen fragments to T cells through MHC molecules. Appropriate costimulation and local signals also matter.
  3. Adaptive response: CD4 cells help coordinate, CD8 cells kill appropriate targets, and B cells can become antibody-secreting plasma cells. Some B-cell responses are T-independent. Memory can accelerate later responses, but its protection and durability vary by antigen.
  4. Regulation: regulatory T cells, inhibitory signals, and clearance of dead cells limit injury and support resolution. Persistent activation should not be mistaken for health.[29][36]
Figure 1 · Immune activation pathway
Teaching illustration · values are not validated clinical measurements
Immune activation pathway
Green denotes TLR recognition, blue phagocytosis, and red T/B responses. Both axes use arbitrary units to illustrate interacting tasks, not a measured infection timetable; the responses can overlap.[29][36]
Supplementary Figure S2 · Recognition, presentation, effectors, and memory
Recognition and early controlPattern-recognition receptorsPhagocytosis, complement, signalsPresentation and activationDendritic cells carry informationMHC + costimulation / signalsT-cell effectorsCD4: coordination and helpCD8: target-cell killingB cells and antibodiesAntigen recognition, appropriate helpPlasma cells secrete antibodiesRegulation, resolution, and memoryLimit injury, clear dead cells, support repairSome T/B cells form memory; durability varies by antigenPathways overlap and vary by pathogen; this is not a fixed sequence or a measured time course.
Qualitative teaching schematic. T/B pathways interact; some B-cell responses are T-independent. This is not a universal time sequence or biomarker trajectory.[29][36]
Figure 2 · Cytokine dynamics during an immune response
Teaching illustration · values are not validated clinical measurements
Cytokine dynamics during an immune response
Red IL-6 and green IL-10 illustrate mobilization and regulation. The concentrations and peaks are not supported by an identifiable dataset and are not human reference ranges or predictions. Actual effects and timing depend on tissue, stimulus, and assay.[29][33]
Supplementary Figure S3 · Cytokines: context determines function
Mobilize and controlIL-1, IL-6, TNF and othersSupport responses in contextRegulate and restrainIL-10, TGF-β and othersLimit injury; may also restrain clearanceSurvival and differentiationIL-2, IL-7 and othersEffects depend on cells and conditionsNo universal cytokine peak curve: dose, timing, tissue, and receptor context shape the effect.
Teaching diagram, not three mutually exclusive classes or measured IL-6/IL-10 peaks. One molecule can participate in several processes.[29][33]
Demonstration · Demonstration: immune-response dynamics
Teaching illustration · values are not validated clinical measurements
Demonstration: immune-response dynamics
Green denotes macrophages, red T cells, and blue antibodies. This illustration explores overlapping tasks and delayed responses, not a validated physiological model. Negative values have no meaning as actual concentrations or cell counts; the curves cannot predict an individual infection.[29][36]

Immune trajectories and influencing factors

Immune aging involves remodeling of thymic output, receptor repertoires, cell subsets, tissue environments, and existing memory. Timing and direction differ. Human atlases published in 2025 show complex, partly nonlinear trajectories rather than one immunity percentage.[3][4]

Other influences

Figure 3 · Factors influencing immune decline
Teaching illustration · values are not validated clinical measurements
Factors influencing immune decline
Age, genetics, diet, stress, and comorbidities jointly shape immunity. The radar scores have no validated scale and do not represent contributions, factor rankings, or individual risk. Read the diagram as a multifactorial framework.[30][31][37]
Supplementary Table S3. Influences and interpretation
FactorConsiderationsLimits
Genetics and exposureHLA background, past infection, and environment shape responsesNo universal radar score assigns personal factor weights [30][37]
Nutrition / metabolic healthDeficiency, eating difficulty, and chronic illness affect needs and recoveryCorrecting a gap differs from high-dose use for everyone [5]
Stress and sleepPersistent stress, sleep, and living conditions can interactAssociation does not prove one hormonal mechanism [18][31]
Disease and medicationImmunosuppression, chronic illness, and tissue context matterAge or one blood marker cannot define all risk [37]
Figure 4 · Age-related changes in immune-cell function
Teaching illustration · values are not validated clinical measurements
Age-related changes in immune-cell function
Counts, migration, phagocytosis, killing, and thymic output are distinct measurements. The percentages are illustrative settings without a common supporting assay dataset, not fixed functional levels for everyone over 65.[3][4][38][42]
Supplementary Figure S4 · Dimensions of immune aging
Cell compositionNaive / memory balance shiftsNot every cell declinesResponse functionSome new-antigen responses weakenChanges differ by cell and tissueChronic inflammationLow-grade inflammation in someNot the whole explanationIndividual variationHealth, exposures, nutrition matterAge alone cannot predict all riskQualitative schematic: no universal immunity percentage or age-decline curve applies to everyone.
Qualitative synthesis of 2025 human immune-atlas research. Cells and tissues change differently; the diagram does not assign a universal functional percentage.[3][4]
Supplementary Table S2. Human immune-aging studies published in 2025
StudyPopulation / methodsContributionLimits
Wang et al., 2025220 healthy volunteers; 13 age groups, birth to >90; single-cell/receptor sequencing and mass cytometryAge-related changes in cell composition, expression, and receptorsLargely cross-sectional; no life-course follow-up or prevention intervention [3]
Gong et al., 2025>300 healthy adults, 25-90; 96 followed for 2 years with influenza vaccination; multi-omicsNonlinear T-cell remodeling linked to B-cell vaccine responsesMainly blood sampling; not a public intervention trial. Publisher lists a 2026 correction [4]

Effects on key body functions

Immune aging can affect key functions, with outcomes also shaped by illness, exposure, treatment, and the pathogen:

Figure 5 · Vaccine responses across age groups
Teaching illustration · values are not validated clinical measurements
Vaccine responses across age groups
The axis depicts seroconversion rather than prevention of illness. The bars lack a traceable trial and serve only to introduce age/dose comparisons. Supplementary Figure S7 gives a clinical influenza example.[13][22]
Supplementary Figure S7 · Influenza vaccination: relative and absolute differences
2026-10-11T21:30:14.481334 image/svg+xml Matplotlib v3.11.2, https://matplotlib.org/
U.S./Canada, adults ≥65, 2011-12 and 2012-13; 31,989 randomized participant-seasons, including reenrollment. Follow-up 6-8 months after vaccination. Bars use published rounded percentages. Full analysis set: high dose 228/15,990, standard 301/15,993. Relative efficacy 24.2% (95% CI 9.7-36.5); rounded absolute difference about 0.5 percentage points, not a 24.2-point increase in protection.[13]

Strategies to support immunity and address immune decline

1. Calorie restriction (CR)

Effects and mechanisms: Nutrient sensing, mTOR, sirtuins, and other pathways are research questions; mechanistic changes do not establish clinical protection. Pathway effects require regimen-specific validation. CALERIE-related human trials were not older-adult trials. Inflammatory/thymic changes do not establish fewer infections or better vaccine protection.[14][15]

Access and practice: Suitability, food access, and adequate nutrition matter; self-directed restriction is particularly inappropriate with underweight, frailty, or inadequate nutrition.

2. Exercise

Effects and mechanisms: Activity supports metabolic, functional, and overall health. IL-7, stress signals, and cell changes are mechanistic topics, not promises of doubled T proliferation or 20% more NK activity. Respiratory-infection trials did not clearly show consistently lower incidence or shorter individual episodes; some symptom-burden results favored activity.[19]

Access and practice: Walking can fit daily life. WHO generally recommends 150–300 minutes of moderate aerobic activity weekly or equivalent vigorous activity, plus strengthening on at least two days; older adults should also address balance. Adapt gradually to capacity. This is health guidance, not an immune-cell dose.[20]

Related support: Maintain regular sleep and address persistent insomnia. A viral-challenge study linked sleep with cold risk but did not randomize sleep. Cleaner air, hand hygiene, reducing contact while ill, and appropriate masking at higher risk can contribute to prevention.[18][21]

3. Vaccination strategies

Effects and mechanisms: Vaccines develop disease-specific protection. Antibodies and clinical illness are different outcomes; Supplementary Figure S7 gives a high-dose influenza example with relative/absolute effects and limits. [13]

Access and practice: Follow current local age-, health-, and prior-dose guidance. The cited CDC schedule is U.S. guidance, not automatically a rule elsewhere.[22]

4. Drug interventions

Metformin: Metabolic/immune mechanisms are research topics; diabetes treatment is not evidence of general-population infection prevention.[27]

Rapamycin-related pathways: Early everolimus antibodies and later RTB101 clinical outcomes require separate interpretation and cannot be renamed as one drug effect.[16][17]

Senolytics: Early patient studies do not establish healthy-person NK restoration or immune rejuvenation. Medical indication, prescription requirements, and experimental status matter more than availability alone.[26]

Supplementary Table S5. Evidence boundaries for investigational interventions
TopicPopulation / designSupported interpretationLimits
Calorie restrictionCALERIE-related trial: 218 non-obese adults, 20-50; 2 years; later mechanism studyInflammation changed without clear infection or vaccine-antibody improvement; thymic/metabolic findings do not prove prevention [14][15]Participants were non-obese adults aged 20–50; results cannot directly guide people with frailty or underweight.
mTOR-related drugs2014 everolimus vaccine-response trial; 2021 RTB101 phase 3Early antibody improvements did not establish later clinical efficacy; Supplementary Figure S8 [16][17]Different drugs cannot be described as the same rapamycin effect or routine healthy-person intervention.
SenolyticsRepresentative early trial: 14 pulmonary-fibrosis patients; open-label, single armFeasibility / physical-function observations do not prove NK restoration or infection prevention in healthy people [26]Disease-specific efficacy and safety need testing; not a public supplement plan.
MetforminPrescription diabetes drug; this review found insufficient clinical evidence for general-population infection preventionEstablished treatment use differs from anti-aging / immunity hypotheses [27]Use according to a medical indication, not self-directed immune enhancement.
Supplementary Figure S8 · RTB101: phase 3 primary outcome not met
2026-10-11T21:30:14.600028 image/svg+xml Matplotlib v3.11.2, https://matplotlib.org/
Adults ≥65, 16 weeks; full analysis set: RTB101 10 mg/day 134/511, placebo 125/510. Percentages calculated from counts to one decimal (publication rounds to 26% and 25%). OR 1.07 (90% CI 0.80-1.42), p=0.65. Outcome: symptomatic respiratory illness, not necessarily laboratory-confirmed infection. Bars have no error bars; inference relies on the reported OR and CI.[17]

5. Nutritional supplementation

Vitamin D, zinc, and omega-3 involve different needs and evidence. Nutritional adequacy, mechanisms, infection prevention, and symptom relief require separate interpretation.[5][7][9][11]

5.1 Build a sustainable dietary foundation

Immune cells and tissues need sufficient energy, protein, and micronutrients. Correcting a genuine deficiency can be necessary; extra supplementation when intake is already adequate does not automatically prevent infection.[5]

Use a varied pattern of produce, whole grains, beans, nuts or seeds, and suitable protein sources such as tofu, eggs, dairy, fish, or poultry. WHO recommends at least 400 g of fruits and vegetables and 25 g of naturally occurring dietary fibre daily for people older than 10. These are general dietary targets, not immune-enhancement doses. Allergies, illness, poor absorption, and limited food intake may require adaptation.[6]

A meal example: combine wholegrain rice or another suitable staple with tofu, fish, or eggs and two vegetables. Add fruit, unsweetened dairy, or suitable fortified foods according to individual needs. This illustrates dietary variety; it is not a clinically tested infection-prevention menu.

5.2 Prevention, shorter illness, and treating deficiency are different questions

Supplementary Table S4. Supplement evidence answers different questions
ProductEvidenceFindingPractical interpretation
Vitamin D2025 RCT meta-analysisNo statistically significant overall protection; Supplementary Figure S5 [7]Meet needs; assess relevant deficiency risk. Not an infection treatment.
Vitamin CCochrane 2013; regular useGeneral community: 24 comparisons, 10,708 participants; RR 0.97 (95% CI 0.94-1.00). Duration: 8% shorter in adults, 14% in children [8]Shorter illness differs from prevention; starting after symptoms has inconsistent evidence.
ZincCochrane 2024Little or no prevention; possible shorter illness with low-certainty evidence and more non-serious adverse events [9]Formulations/doses vary; avoid prolonged high doses and check interactions. Avoid nasal zinc products.[28]
ProbioticsCochrane 2022Possible fewer upper respiratory infections; products and populations vary [10]Do not generalize across strains. Seek advice with severe immunosuppression.[5]
Omega-3DO-HEALTH / 2025 post hoc analysisTotal-infection primary outcome not significant; aging measurements are surrogate outcomes [11][12]Dietary value does not establish universal infection prevention or a fixed anti-inflammatory percentage.
Supplementary Figure S5 · Vitamin D and acute respiratory infection
2026-10-11T21:30:14.246381 image/svg+xml Matplotlib v3.11.2, https://matplotlib.org/
Redrawn from Jolliffe et al. (2025): 40 RCTs, 61,589 participants; OR 0.94 (95% CI 0.88-1.00), p=0.057. Ages, doses, and follow-up differ across trials. Published rounded values; OR is not an absolute risk reduction.[7]
Reading Supplementary Figure S5: OR means odds ratio; 1 means no difference. The dot is the effect estimate and the line is its 95% confidence interval. The published upper limit rounds to 1.00 and p=0.057, above the conventional significance threshold. This does not establish protection, but it also does not prove zero benefit in every circumstance.

5.3 Omega-3: mechanisms, infections, and biological-age measurements

DO-HEALTH randomized 2,157 relatively healthy adults aged 70 or older in a 2×2×2 factorial design, testing vitamin D, marine omega-3, and home strength exercise over approximately three years. The prespecified total-infection outcome did not meet the trial’s stricter significance threshold for multiple comparisons. Some post hoc infection-subtype findings warrant further testing.[11]

Supplementary Figure S6 · DO-HEALTH: clinical infection outcomes
2026-10-11T21:30:14.361325 image/svg+xml Matplotlib v3.11.2, https://matplotlib.org/
Redrawn published adjusted contrasts (Tables 2 and 3). Trial: 2,157 randomized adults ≥70, about 3 years; vitamin D 2,000 IU/day, marine omega-3 1 g/day, strength exercise 30 min three times weekly; corresponding placebo/flexibility controls. Lines are 99%, not 95%, CIs; trial significance threshold p<0.01. These rate ratios cannot rank interventions against Supplementary Figures S5 or S7.[11]

A 2025 post hoc analysis of 777 trial participants found small changes in some DNA-methylation aging measures with omega-3. These research measurements cannot be directly translated into extra months of life or proof of immune restoration or fewer infections. Neither they nor anti-inflammatory mechanisms justify a universal “40% IL-6 reduction” claim.[12]

5.4 Dose boundaries

For generally healthy adults aged 19 or older, tolerable upper intake levels are vitamin C 2,000 mg/day, vitamin D 100 μg (4,000 IU)/day, and zinc 40 mg/day from all sources. These are safety ceilings, not targets; children have different limits. Prolonged excess zinc can cause copper deficiency; excess vitamin D can cause hypercalcemia. Clinician-directed deficiency treatment may differ.[23][24][25]

Figure 6 · Interventions and T-cell proliferation
Teaching illustration · values are not validated clinical measurements
Interventions and T-cell proliferation
These four curves illustrate intervention research questions, not a comparative trial in one population using one assay. The curves and fold changes cannot rank efficacy; actual drugs, doses, populations, and endpoints require separate interpretation.[14][15][16][17][19]
Figure 7 · Supplements and IL-6 reduction
Teaching illustration · values are not validated clinical measurements
Supplements and IL-6 reduction
The 40/35/25% shares lack a traceable trial and are not clinical effects of the three supplements. Separate intervention reductions do not form additive parts of one whole; IL-6 changes and infection prevention are different endpoints.[5][7][9][11]
Figure 8 · Thymic output across age
Teaching illustration · values are not validated clinical measurements
Thymic output across age
Thymic output generally falls with age, but these percentage points are not linked to an identifiable human dataset and cannot calculate immune age. Adult naive cells also depend on peripheral maintenance, with differences between humans and mice.[35][42]

Table: accessibility of interventions

Table 1. Intervention accessibility and practical considerations
InterventionAccessibilityChallengesAdvice
Calorie restrictionRequires planning; nutritional support/follow-up may be needed.Nutritional inadequacy, underweight, frailty, and illness.Assess suitability; research restriction percentages are not universal targets. [14][15]
ExerciseWalking and similar activities are accessible and adaptable.Mobility, cardiopulmonary, and pain limitations.Start at a manageable level; include strength/balance and adapt as needed. [20]
High-dose vaccinesDepends on healthcare access, age, and local recommendations.Cost, supply, and eligibility recommendations.Follow current local guidance; a historical trial is not a result for every vaccine. [13][22]
Metformin / rapamycinPrescription drugs requiring an indication, assessment, and monitoring.Indications, adverse effects, interactions, and monitoring.Use for an appropriate medical indication, not self-directed immune enhancement. [16][17][27]
SenolyticsInvestigational; evidence for routine general-population use is insufficient.Unestablished general-population benefit and incomplete safety evidence.Await specific research results; do not self-combine agents. [26]
Vitamin D / zincOften readily available; cost varies by region/formulation.Excess, prolonged use, and interactions.Supplement according to need; upper limits are not targets. [24][25]
Omega-3Available through foods/supplements, with varying choices and costs.Food choice, formulation, dose, tolerability, and medications.Distinguish ALA from EPA/DHA; dietary value is not proof of infection protection. [11][43]

Access, costs, and medical rules vary by region. Decisions also depend on health, expected benefit, risks, and sustainability.

Conclusion

The immune system coordinates defense, tolerance, memory, and repair. Aging, genetics, nutrition, stress, illness, and exposure remodel this network without a single fixed percentage of weakening. Practical priorities include adequate nutrition, appropriate vaccination, sustainable activity and sleep, reduced higher-risk exposure, and care for relevant health conditions.

Calorie restriction and investigational drugs require population-, dose-, and outcome-specific interpretation. Supplement mechanisms do not establish clinical protection for everyone. The key is to connect plausible biology with reliable human outcomes and choose actions that match individual needs.[5][13][14][17][20]

Study summaries

The summaries explain where evidence comes from, how it is studied, and what questions it can answer. Cell experiments, immune atlases, mechanistic reviews, and randomized human trials have different purposes.

1. Neutrophils

Human-cell experiment

Sapey and colleagues compared neutrophil migration in healthy younger and older donors and tested PI3K inhibition in the laboratory. Directional accuracy and movement capacity are distinct measurements; cell experiments do not directly establish fewer clinical infections.[38]

2. NK cells

Human immune atlases

Single-cell, receptor, and cellular profiling characterize NK subsets and age-related changes. Abundance or gene expression is not a killing assay; functional studies need defined stimulation and assay conditions.[3][4][37]

3. Thymic involution

Human/mouse mechanistic comparison

den Braber and colleagues compared naive T-cell maintenance in humans and mice, highlighting peripheral maintenance in adult humans. Lower thymic output does not mean a proportional loss of the cell pool, and animal findings cannot define a human age curve.[35][42]

4. T cells

Mechanistic review and human atlases

Goronzy and Weyand review T-cell aging through naive-cell maintenance, metabolism, and signaling; 2025 human atlases add subset trajectories. Telomeres, counts, and functional assays do not combine into one universal loss percentage.[3][4][42]

5. B cells

Human vaccine-mechanism study

Turner and colleagues studied blood in 41 vaccine recipients and draining lymph nodes in 14. Antigen-specific B-cell and receptor analyses illustrate germinal-centre responses, not a standalone measure of clinical protection or universal age differences.[41]

6. Macrophages and wound healing

Cell-state and tissue-repair reviews

Macrophages contribute clearance, repair, remodeling, and fibrosis. M1/M2 simplifies experimental states; tissue, stimulus, and timing shape actual behavior. Animal wound mechanisms require human evidence for clinical translation.[2][33]

7. Cytokine profiles

Human age-related profiling

Human atlases combine cellular and molecular profiling across ages. Some remodeling is not fully explained by systemic inflammation. Marker–disease associations differ from evidence that lowering a marker prevents illness.[3][4]

8. Tumor immunity

Cancer-immunity conceptual review

Immunoediting includes elimination, equilibrium, and escape. Immune responses can constrain tumors, while tumors can alter their immune environment. One infiltration measure, cancer type, or model cannot define overall antitumor capacity.[32]

9. Vaccine responses

Interpreting vaccine endpoints

Haemagglutination-inhibition titres, seroconversion, confirmed illness, and severe disease are different endpoints. Protection requires vaccine-, population-, and follow-up-specific interpretation; Supplementary Figure S7 illustrates clinical influenza rather than antibodies alone.[13]

10. Calorie restriction in mice

Interpreting animal studies across species

Animal and cellular studies explore energy intake, nutrient sensing, and immunity. Housing, restriction level, and pathogen challenge influence results. Human strategies require human trials rather than direct adoption of an animal restriction percentage.[14][15]

11. Calorie restriction in humans

Randomized human nutritional intervention

CALERIE-related research involved 218 non-obese adults aged 20–50 over two years. Inflammatory changes did not establish infection or vaccine-antibody benefits; thymic/immunometabolic observations from a 2022 substudy are not disease-prevention outcomes.[14][15]

12. Aerobic exercise

Synthesis of exercise trials

The exercise synthesis did not clearly establish fewer respiratory-infection episodes or shorter individual episodes, although some symptom-burden findings favored activity. WHO guidance supports overall health, not a promise of doubled T-cell proliferation.[19][20]

13. Resistance training

Randomized activity intervention in older adults

DO-HEALTH studied home strength exercise in adults ≥70 for about three years and assessed clinical infections. Laboratory NK measurements and actual illness answer different questions; general activity advice must also account for capacity and health.[11][20]

14. Vaccine dose

Randomized influenza-vaccine comparison

DiazGranados and colleagues compared high-dose and standard-dose influenza vaccines in adults ≥65 across two seasons. Confirmed influenza was approximately 1.4% versus 1.9%. Relative efficacy was 24.2%, with a rounded absolute difference of about 0.5 percentage points; the measures answer different questions.[13]

15. mRNA vaccines

Clinical and mechanistic mRNA-vaccine research

Polack’s randomized trial assessed COVID-19 illness; Turner’s study examined blood and lymph-node B-cell responses. These provide complementary evidence. Historical pandemic/product results are not fixed efficacy estimates for current variants or every vaccine.[40][41]

16. Metformin

Established medical use and research hypotheses

Metformin is a prescription diabetes drug. Metabolic/immune links merit research, but established diabetes treatment does not demonstrate infection prevention, immune rejuvenation, or longer life in healthy people.[27]

17. Rapamycin

Human trials of mTOR-related drugs

A 2014 everolimus study observed improved vaccine antibodies; the 2021 RTB101 phase 3 trial did not meet its primary clinical endpoint. Rapamycin, everolimus, and RTB101 are not interchangeable; antibodies, illness, and human lifespan require different evidence.[16][17]

18. Senolytics

Early patient trial

An early human senolytic study involved 14 pulmonary-fibrosis patients in an open-label, single-arm design. Feasibility and physical-function observations do not establish NK restoration, infection prevention, or longer life in healthy people.[26]

19. Vitamin D

Cell mechanisms and randomized-trial synthesis

Liu and colleagues studied TLR/vitamin-D signaling, cathelicidin, and intracellular tuberculosis in human macrophages: mechanistic evidence. The 2025 comparison of 40 trials reported OR 0.94 (95% CI 0.88–1.00), p=0.057; mechanism and overall clinical protection require separate interpretation.[39][7]

20. Omega-3

Clinical infections and surrogate measures

DO-HEALTH examined clinical infections in adults ≥70 over about three years, using 99% intervals and a multiplicity threshold. Its 2025 methylation-clock substudy is not an infection or longevity trial; inflammatory markers, infections, and biological age remain distinct.[11][12]

References

The numbered references correspond to citations in the text:

  1. National Institute of Allergy and Infectious Diseases. Overview of the Immune System. Official educational resource. Publication
  2. Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14-20. doi:10.1016/j.immuni.2014.06.008. Publication
  3. Wang Y, Li R, Tong R, et al. Integrating single-cell RNA and T cell/B cell receptor sequencing with mass cytometry reveals dynamic trajectories of human peripheral immune cells from birth to old age. Nature Immunology. 2025;26:308-322. doi:10.1038/s41590-024-02059-6. Publication
  4. Gong Q, Sharma M, Glass MC, et al. Multi-omic profiling reveals age-related immune dynamics in healthy adults. Nature. 2025;648:696-706. doi:10.1038/s41586-025-09686-5. Publisher page notes an author correction dated 10 April 2026. Publication
  5. NIH Office of Dietary Supplements. Dietary Supplements for Immune Function and Infectious Diseases: Fact Sheet for Health Professionals. Continuously updated; accessed 11 October 2026. Publication
  6. World Health Organization. Healthy diet. Fact sheet, 26 January 2026. Publication
  7. Jolliffe DA, Camargo CA Jr, Sluyter JD, et al. Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data. Lancet Diabetes & Endocrinology. 2025;13(4):307-320. doi:10.1016/S2213-8587(24)00348-6. Linked correction: 2025;13(7):e10, doi:10.1016/S2213-8587(25)00158-5. Publication
  8. Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database of Systematic Reviews. 2013;(1):CD000980. doi:10.1002/14651858.CD000980.pub4. Publication
  9. Nault D, Machingo TA, Shipper AG, et al. Zinc for prevention and treatment of the common cold. Cochrane Database of Systematic Reviews. 2024;(5):CD014914. doi:10.1002/14651858.CD014914.pub2. Publication
  10. Zhao Y, Dong BR, Hao Q. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database of Systematic Reviews. 2022;(8):CD006895. doi:10.1002/14651858.CD006895.pub4. Publication
  11. Bischoff-Ferrari HA, Vellas B, Rizzoli R, et al. Effect of vitamin D supplementation, omega-3 fatty acid supplementation, or a strength-training exercise program on clinical outcomes in older adults: the DO-HEALTH randomized clinical trial. JAMA. 2020;324(18):1855-1868. doi:10.1001/jama.2020.16909. Publication
  12. Bischoff-Ferrari HA, Gängler S, Wieczorek M, et al. Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial. Nature Aging. 2025;5:376-385. doi:10.1038/s43587-024-00793-y. Publication
  13. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. New England Journal of Medicine. 2014;371(7):635-645. doi:10.1056/NEJMoa1315727. Publication
  14. Meydani SN, Das SK, Pieper CF, et al. Long-term moderate calorie restriction inhibits inflammation without impairing cell-mediated immunity: a randomized controlled trial in non-obese humans. Aging (Albany NY). 2016;8(7):1416-1426. doi:10.18632/aging.100994. Publication
  15. Spadaro O, Youm Y, Shchukina I, et al. Caloric restriction in humans reveals immunometabolic regulators of health span. Science. 2022;375(6581):671-677. doi:10.1126/science.abg7292. Publication
  16. Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Science Translational Medicine. 2014;6(268):268ra179. doi:10.1126/scitranslmed.3009892. Publication
  17. Mannick JB, Teo G, Bernardo P, et al. Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials. Lancet Healthy Longevity. 2021;2(5):e250-e262. doi:10.1016/S2666-7568(21)00062-3. Publication
  18. Cohen S, Doyle WJ, Alper CM, Janicki-Deverts D, Turner RB. Sleep habits and susceptibility to the common cold. Archives of Internal Medicine. 2009;169(1):62-67. doi:10.1001/archinternmed.2008.505. Publication
  19. Grande AJ, Keogh J, Silva V, Scott AM. Exercise versus no exercise for the occurrence, severity, and duration of acute respiratory infections. Cochrane Database of Systematic Reviews. 2020;(4):CD010596. doi:10.1002/14651858.CD010596.pub3. Publication
  20. World Health Organization. WHO guidelines on physical activity and sedentary behaviour: at a glance. Geneva: WHO; 2020. ISBN 9789240014886. Publication
  21. U.S. Centers for Disease Control and Prevention. Preventing Spread of Respiratory Viruses When You’re Sick. Public guidance; accessed 11 October 2026. Publication
  22. U.S. Centers for Disease Control and Prevention. Adult Immunization Schedule by Age. Current U.S. schedule; accessed 11 October 2026. Publication
  23. NIH Office of Dietary Supplements. Vitamin C: Fact Sheet for Health Professionals. Accessed 11 October 2026. Publication
  24. NIH Office of Dietary Supplements. Vitamin D: Fact Sheet for Health Professionals. Accessed 11 October 2026. Publication
  25. NIH Office of Dietary Supplements. Zinc: Fact Sheet for Health Professionals. Accessed 11 October 2026. Publication
  26. Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554-563. doi:10.1016/j.ebiom.2018.12.052. Publication
  27. National Library of Medicine. Metformin. MedlinePlus Drug Information; revised 15 February 2024. Publication
  28. National Center for Complementary and Integrative Health. Colds, Flu, and Complementary Health Approaches: Usefulness and Safety. Official safety guidance; accessed 11 October 2026. Publication
  29. Chaplin DD. Overview of the immune response. Journal of Allergy and Clinical Immunology. 2010;125(2 Suppl 2):S3-S23. doi:10.1016/j.jaci.2009.12.980. Publication
  30. Brodin P, Jojic V, Gao T, et al. Variation in the human immune system is largely driven by non-heritable influences. Cell. 2015;160(1-2):37-47. doi:10.1016/j.cell.2014.12.020. Publication
  31. Cohen S, Tyrrell DA, Smith AP. Psychological stress and susceptibility to the common cold. New England Journal of Medicine. 1991;325(9):606-612. doi:10.1056/NEJM199108293250903. Publication
  32. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565-1570. doi:10.1126/science.1203486. Publication
  33. Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity. 2016;44(3):450-462. doi:10.1016/j.immuni.2016.02.015. Publication
  34. Netea MG, Domínguez-Andrés J, Barreiro LB, et al. Defining trained immunity and its role in health and disease. Nature Reviews Immunology. 2020;20(6):375-388. doi:10.1038/s41577-020-0285-6. Publication
  35. den Braber I, Mugwagwa T, Vrisekoop N, et al. Maintenance of peripheral naive T cells is sustained by thymus output in mice but not humans. Immunity. 2012;36(2):288-297. doi:10.1016/j.immuni.2012.02.006. Publication
  36. Murphy K, Weaver C. Janeway’s Immunobiology. 9th ed. New York: Garland Science/Taylor & Francis; 2017. ISBN 9780815345053. Background textbook. Publication
  37. Brodin P, Davis MM. Human immune system variation. Nature Reviews Immunology. 2017;17(1):21-29. doi:10.1038/nri.2016.125. Publication
  38. Sapey E, Greenwood H, Walton G, et al. Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence. Blood. 2014;123(2):239-248. doi:10.1182/blood-2013-08-519520. Publication
  39. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770-1773. doi:10.1126/science.1123933. Publication
  40. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine. 2020;383:2603-2615. doi:10.1056/NEJMoa2034577. Historical trial, not an estimate for current variants or products. Publication
  41. Turner JS, O’Halloran JA, Kalaidina E, et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature. 2021;596:109-113. doi:10.1038/s41586-021-03738-2. Publication
  42. Goronzy JJ, Weyand CM. Mechanisms underlying T cell ageing. Nature Reviews Immunology. 2019;19:573-583. doi:10.1038/s41577-019-0180-1. Mechanistic review. Publication
  43. NIH Office of Dietary Supplements. Omega-3 Fatty Acids: Fact Sheet for Health Professionals. Accessed 13 October 2026. Publication

Supplementary explanations

1. Neutrophils: early responders

Neutrophils are abundant circulating white cells that can rapidly reach a threat.

Functions / research focus

  • Chemotaxis: migration along chemical signals.
  • Phagocytosis: uptake and processing of microbes/debris.
  • Degranulation: release of antimicrobial material.
  • NETs: extracellular DNA/protein structures in some conditions; these can also injure tissue.

Aging, interventions, and interpretation

Aging studies distinguish speed, directional accuracy, engulfment, and inflammatory release. Sapey’s experiment informs migration/PI3K questions, not a universal loss across all functions or a self-medication plan.[29][38]

2. NK cells: rapid responses to some abnormal targets

NK cells use a recognition strategy distinct from classical T-cell receptors and integrate multiple signals rather than automatically killing every low-MHC cell.

Functions / research focus

  • Perforin and granzymes contribute target-cell killing.
  • IFN-γ and other signals affect neighboring cells.
  • Missing-self recognition is one mechanism; activating ligands and inhibitory receptors also matter.

Aging, interventions, and interpretation

Counts and function depend on subsets, viral exposure, and assays. Killing, metabolism, and cancer outcomes require separate research; improving a laboratory marker has not established public cancer prevention.[3][29][32][37]

3. Thymic involution: an age-sensitive source of new T cells

The thymus behind the breastbone supports T-cell maturation and selection; output generally falls with age.

Functions / research focus

  • Bone-marrow precursors enter the thymus.
  • Selection works with other tolerance mechanisms to limit self-reactivity.
  • New naive cells add to receptor-repertoire sources.

Aging, interventions, and interpretation

Involution does not mean all immunity disappears: peripheral maintenance and memory remain important. Human/mouse mechanisms differ; animal hormonal interventions do not directly define human advice or an individual age curve.[35][36][42]

4. T cells: help, killing, and restraint

T cells arise from marrow precursors, mature in the thymus, and participate in antigen-specific responses.

Functions / research focus

  • CD4 helper cells coordinate T/B and other effector responses.
  • CD8 cells kill targets displaying relevant antigen.
  • Regulatory T cells restrain excessive activity.
  • Naive/memory describes antigen experience, not categories identical to CD4/CD8.

Aging, interventions, and interpretation

Repertoire diversity, telomeres, metabolism, inflammation, and persistent infection affect subsets differently. Memory can protect against known threats while accompanying structural change; more memory cells do not automatically mean weaker immunity.[3][4][42]

5. B cells: antibodies and memory

B cells can become plasma cells or memory cells. Antibodies can neutralize, label targets, and support other clearance mechanisms.

Functions / research focus

  • Germinal centres support affinity maturation.
  • Class switching changes antibody class; it is not identical to increased affinity.
  • Some responses occur outside germinal centres or without T-cell help.

Aging, interventions, and interpretation

Age-related changes require tissue and antigen context. Post-vaccine antibodies, memory, and clinical protection are different outcomes; affinity and diversity require study-specific interpretation.[29][36][41]

6. Macrophages: clearance, coordination, and repair

Macrophages occupy many tissues and contribute infection control, homeostasis, and injury responses.

Functions / research focus

  • Engulf microbes, dead cells, and debris.
  • Release signals and participate in antigen presentation.
  • Contribute repair/remodeling and sometimes fibrosis.

Aging, interventions, and interpretation

M1/M2 is not a fixed binary. Tissue, stimulus, and timing shape state; the same growth factor may support repair or pathology. Healing requires attention to local conditions and overall health.[2][33]

7. Cytokines: immune-system messengers

Cytokines from immune and other cells transmit local and systemic information.

Functions / research focus

  • IL-1, IL-6, and TNF contribute mobilization and inflammation.
  • IL-10 and TGF-β regulate responses and can also limit clearance.
  • IL-2/IL-7 support particular cellular processes in context.
  • Type I interferons and IFN-γ have distinct, overlapping defense roles and are not interchangeable.

Aging, interventions, and interpretation

Inflammaging is a population/mechanistic concept, not an immune-age diagnosis from one IL-6 measurement. Marker changes can be associated with or contribute to mechanisms; suppressing every inflammatory signal is not necessarily healthy.[4][29][33]

8. Calorie restriction: nutrition, metabolism, and immunity

Research calorie restriction reduces energy while preserving essential nutrition. Regimens vary; research restriction percentages are not universal public targets.

Functions / research focus

  • Studies examine nutrient sensing, mTOR, and other metabolic signals.
  • Cell/animal mechanisms generate human questions.
  • Human studies distinguish inflammation, thymic measures, and clinical outcomes.

Aging, interventions, and interpretation

CALERIE-related work was not an older-adult trial. Inflammation or thymic changes do not prove vaccine/infection protection. Self-directed restriction may be inappropriate with malnutrition, underweight, frailty, or illness. Lifespan results from other species cannot be transferred directly.[14][15]

9. Metformin: established treatment and research hypotheses

Metformin is a prescription treatment for type 2 diabetes; links between metabolism and immunity motivate further research.

Functions / research focus

  • AMPK, nutrient sensing, and inflammatory pathways are research questions.
  • Model CD8 or vaccine effects require specific drug/dose/population evidence.
  • Established treatment does not establish healthy-person anti-aging effects.

Aging, interventions, and interpretation

Anti-aging and immunomodulation research does not establish general-population infection prevention or longer life. Treatment requires a medical indication and safety assessment.[27]

10. Rapamycin: mTOR and immune modulation

Rapamycin (sirolimus) has immunosuppressive uses; immune effects depend on the drug, dose, timing, and population.

Functions / research focus

  • mTOR influences growth and metabolism.
  • Low-dose studies do not generalize to every formulation/regimen.
  • Everolimus, rapamycin, and RTB101 are not interchangeable effects.

Aging, interventions, and interpretation

The 2014 everolimus antibody improvement does not establish longer human life or clinical benefit; RTB101 phase 3 did not meet its primary endpoint. Drug, dose, and regimen affect both outcomes and immunosuppressive risks.[16][17]

11. Senolytics: investigating selective cell clearance

Senescent cells generally show stable growth arrest and context-dependent secretory activity (SASP). Senescence is not simply every old cell refusing to die.

Functions / research focus

  • Clearance, secretory signals, and tissue repair are different endpoints.
  • Dasatinib/quercetin combinations need specific human evidence.
  • Fisetin or other names and animal findings do not establish public benefit.

Aging, interventions, and interpretation

Benefits of clearance require validation in particular diseases and tissues. An early single-arm fibrosis trial does not establish healthy-person NK restoration, infection protection, or reversal of immune age; agents and doses should not be self-combined.[26]

12. Vitamin D: needs, mechanisms, and clinical evidence

Vitamin D supports bone/calcium metabolism and participates in immune regulation. Skin synthesis, food, absorption, and liver/kidney metabolism affect status.

Functions / research focus

  • Human macrophage research supports a TLR/vitamin-D/cathelicidin mechanism.
  • Older age, inadequate intake, and some illnesses can increase deficiency risk.
  • Observational deficiency associations do not replace supplementation trials.

Aging, interventions, and interpretation

A mechanism does not mean supplements prevent infection in everyone. The 2025 overall randomized comparison did not reach conventional significance; correcting relevant deficiency remains a separate clinical question. An upper intake limit is a safety ceiling, not a target.[7][24][39]

13. Omega-3: fatty acids and resolution

Fish supplies EPA/DHA; flaxseed and walnuts mainly supply ALA. Conversion to EPA/DHA is limited, so sources are not dose-equivalent.

Functions / research focus

  • Membrane composition and signaling are mechanistic topics.
  • Some EPA/DHA-derived mediators participate in resolution.
  • Inflammation, cardiovascular/cognitive outcomes, and infection protection require separate assessment.

Aging, interventions, and interpretation

DO-HEALTH infections and the 2025 methylation clocks require separate interpretation; dose, tolerability, and concurrent medication matter. Foods, supplements, and prescription formulations are not interchangeable.[11][12][43]